Accuray (NASDAQ: ARAY) — Company Overview, News & Financial Data
Accuray develops advanced radiotherapy systems for cancer treatment, focusing on precise and innovative radiation solutions.
Accuray
Accuray (NASDAQ:ARAY) specializes in the development, manufacturing, and sale of radiotherapy systems for alternative cancer treatments. The company is a pioneer in precise, innovative radiation therapy solutions, focusing on delivering life-extending treatment options to patients battling cancer. Accuray's portfolio includes the CyberKnife and TomoTherapy platforms, which are designed to deliver precise, high-dose radiation therapy with minimal damage to surrounding healthy tissue. With a global footprint, Accuray aims to expand access to its cutting-edge treatments, ensuring healthcare providers can offer advanced care to patients worldwide. The company continuously seeks to enhance its technologies and expand its reach, aiming to improve outcomes and quality of life for cancer patients.
Snapshot
Operations
Products and/or services of Accuray
- The CyberKnife System, a robotic radiosurgery system designed for precise, non-invasive cancer treatments.
- The TomoTherapy System, which combines intensity-modulated radiation therapy with computed tomography (CT) imaging for accurate cancer treatment.
- Radixact Treatment Delivery System, an advanced radiation therapy solution that leverages precise image-guidance for treating a wide range of cancers.
- Synchrony, a real-time motion tracking and correction technology for radiosurgery and radiation therapy, ensuring accurate targeting.
- VOLO Optimizer, a software tool designed to significantly reduce planning times for radiation therapy, improving efficiency and treatment outcomes.
Accuray executive team
- Ali PervaizSenior VP & CFO
- Stephen R. LaNevePresident, CEO & Director
- Michael J. MurphyCorporate Controller & Principal Accounting Officer
- David ShinSenior VP, Chief Legal Officer & Corporate Secretary
Key financials
Reported results for Accuray, in USD.
- Market cap
- 17.1M
- Revenue (TTM)
- 401.9M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.4
- Dividend yield
- —
- Profit margin
- -12.2%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 401.9M | -26.4M | -49.2M | |
| 458.5M | 7.8M | -1.6M | |
| 446.6M | 504K | -15.5M | |
| 447.6M | 2.4M | -9.3M |